TCG Crossover Management LLC Acquires 25,000 Shares of Xencor, Inc. (NASDAQ:XNCR)

TCG Crossover Management LLC boosted its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 1.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,452,138 shares of the biopharmaceutical company's stock after purchasing an additional 25,000 shares during the period. Xencor comprises approximately 5.5% of TCG Crossover Management LLC's investment portfolio, making the stock its 3rd biggest position. TCG Crossover Management LLC owned approximately 3.50% of Xencor worth $56,350,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Northern Trust Corp increased its holdings in Xencor by 19.3% in the fourth quarter. Northern Trust Corp now owns 747,152 shares of the biopharmaceutical company's stock worth $17,170,000 after purchasing an additional 120,655 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Xencor in the 4th quarter valued at $235,000. Birchview Capital LP lifted its position in shares of Xencor by 111.4% during the 4th quarter. Birchview Capital LP now owns 26,000 shares of the biopharmaceutical company's stock valued at $597,000 after acquiring an additional 13,700 shares during the period. Syon Capital LLC bought a new position in Xencor during the fourth quarter worth $224,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Xencor by 2.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company's stock worth $92,758,000 after purchasing an additional 107,350 shares during the period.

Wall Street Analyst Weigh In

XNCR has been the topic of a number of research analyst reports. Wells Fargo & Company cut their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, William Blair assumed coverage on Xencor in a research note on Monday, April 21st. They issued an "outperform" rating for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $33.86.

Xencor Stock Performance

Shares of Xencor stock opened at $10.60 on Tuesday. Xencor, Inc. has a 52 week low of $7.16 and a 52 week high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $11.66 and a 200-day moving average price of $18.33. The company has a market cap of $754.21 million, a PE ratio of -3.31 and a beta of 0.90.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Equities analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.